FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
250
Enrollment
INDUSTRY
Sponsor class
Conditions
Ovarian Cancer
Non-small Cell Lung Cancer
Interventions
DRUG:
TUB-040
Sponsor
Tubulis GmbH